Patent intelligence · US
US 12090139
Formulations comprising triptan compounds
Formulations comprising triptan compounds
Patent details — US 12090139
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 17, 2024
- Expiration
- Sep 12, 2044
- Applicant
- Tonix Medicines, Inc.
- Claims
- 13
- CPC classes
- A61K, A61K31/40, A61K31/404, A61K31/4045
Quick answer
US 12090139 (Formulations comprising triptan compounds) is held by Tonix Medicines, Inc.. Status: granted. Granted Sep 17, 2024. Expires Sep 12, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Tonix Medicines, Inc.
- Grant date
- Expiration
- Claims
- 13
- CPC classes
- A61K, A61K31/40, A61K31/404, A61K31/4045, A61K31/70, A61K31/7028
More from Tonix Medicines, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12383733
Iontophoresis-based patch type medicine absorption device
granted -
US 12365879
Synthetic chimeric poxviruses
granted -
US 12304901
Selective ligands for tau aggregates
granted -
US 12156897
Magnesium-containing oxytocin formulations and methods of use
granted -
US 12156864
Analogs of cyclobenzaprine and amitryptilene
granted -
US 12097183
Pharmaceutical composition for treating migraine
granted -
US 11998516
Methods and compositions for treating depression using cyclobenzaprine
granted
Frequently asked questions
What is US patent 12090139?
US 12090139 (Formulations comprising triptan compounds) is held by Tonix Medicines, Inc.. Status: granted. Granted Sep 17, 2024. Expires Sep 12, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12090139?
Tonix Medicines, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 86 pharmaceutical patents for this assignee.
When does US 12090139 expire?
Our index shows an expiration date of Sep 12, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.